2024 was a challenging yet very productive year for our HAE community. Undoubtedly highlighted by two wonderful international events, the 2024 HAEi Regional Conference Americas and the 2024 HAEi Global Leadership Workshop and ACARE Global Aniogedema Forum 2024 set up the tone for a fantastic year.

The beginning of the year was enhanced by the superb 2024 HAEi Regional Conference Americas in Panama, which provided a unique opportunity for sharing and learning and gave us the chance to meet patients from all over the Americas, thus fostering emotional and social support. Under the conference’s motto, TAKE ACTION, our representatives were enriched by the multiple presentations and activities that took place during two awe-inspiring days.

hae day :-), on 16 May, was yet another interesting highlight of the year. As usual, different activities were organized to promote awareness of HAE. But what made this hae day :-) extremely special was the active involvement of our youngster community.  Our young group gathered not only to adhere to HAEi’s campaign  “Walking for HAE” but also to organize an informal Get-Together, which ended up with a fantastic, fun-filled “Escape Room game” where our youngsters had to find clues, solve clever puzzles, and crack codes all related to HAE. It was amazing to realize how well-informed our younger patients are. We are very happy to see that the HAEi’s Leap program served as a magnificent starting point for getting our youngsters involved.

October found some of our members traveling to Copenhagen, Denmark, to participate in the first Global Angioedema Forum and Global Leadership workshop. The wealth of information shared during this combined event made this quite a unique experience for our group. We got back home inspired and motivated to keep on doing our best to improve HAE patients’ quality of life.

Finally, the end of 2024 found us celebrating another very important milestone for the Argentine patient community: the approval and marketing authorization in our country of yet another prophylactic treatment for HAE, making it now the 3rd medication available to prevent HAE episodes in our country. What better news to close a productive year than to expand our treatment options?

As we move forward to a New Year, we hope  2025 will continue to show greater advances in the study and management of Hereditary Angioedema, with new treatments that result in improved quality of life for all HAE patients around the globe.

May 2025 find our local organization strengthening its advocacy efforts, and may our patients continue to improve access to modern, safe, and effective medications.

May the New Year bring boundless hope for the future of HAE patients.